Replies to post #1868 on Dendreon Corp fka DNDNQ

[rancherho]

Glaxo's Tykerb appears to be a bigger competitive threat (and potential benefit for breast cancer patients) to both DNA's Herceptin and DNDN's Neuvenge. See:http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061214:MTFH96037_2...